| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Rapid Communication |
Division of Reproductive Sciences, Oregon National Primate Research Center, Beaverton, Oregon 97006
Address correspondence to: Robert Brenner, M.D., Division of Reproductive Sciences, Oregon Regional Primate Research Center, 505 NW 185th Street, Beaverton, Oregon 97006. E-mail: brennerr{at}ohsu.edu
Abstract
In addition to blocking progesterone (P) action, antiprogestins (APs) also inhibit estrogen-stimulated endometrial cell proliferation in nonhuman primates and women. This effect is paradoxical because APs do not bind to estrogen receptors (ER), and AP + estradiol (E2) treatment leads to elevation of ER levels, a recognized action of estrogen in the endometrium. Recently, we showed that APs (RU 486, ZK 137 316 and ZK 230 211) also elevate endometrial androgen receptor (AR) in macaques and women and we hypothesized that over expression of AR may play a role in the antiproliferative actions of APs. We now report that cotreatment with the specific antiandrogen flutamide (FLU) blocked the suppressive effects of APs on estrogen action in the endometrium. We treated ovariectomized rhesus macaques with either E2 alone, E2 + ZK 137 316 or E2 + ZK 137 316 + FLU daily for 28 days. Endometrial wet weight (mean ± SE) from one-half of the endometrium was as follows: E2-treated controls, 360 ± 32 mg; E2 + ZK 137 316, 64 ± 10 mg; and E2 + ZK 137 316 + FLU, 265 ± 92 mg (P < 0.05). Mean mitoses/1000 epithelial cells ± SE was: E2 alone, 6.25 ± 0.6; E2 + ZK 137 316, 0.3 ± 0.25; and E2 + ZK 137 316 + FLU, 5.1 ± 3.8 (P < 0.05). FLU also blocked the hyalinizing degradation of the spiral arteries typically induced by APs. These results indicate that many of the antiendometrial effects of APs in primates may involve the AR.
This article has been cited by other articles:
![]() |
M. Engman, L. Skoog, G. Soderqvist, and K. Gemzell-Danielsson The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology Hum. Reprod., September 1, 2008; 23(9): 2072 - 2079. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Heikinheimo, S. Vani, O. Carpen, A. Tapper, P. Harkki, E.-M. Rutanen, and H. Critchley Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study Hum. Reprod., September 1, 2007; 22(9): 2515 - 2522. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zang, L. Sahlin, B. Masironi, E. Eriksson, and A. Linden Hirschberg Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2169 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
O.D. Slayden, M.B. Zelinski, K. Chwalisz, H. Hess-Stumpp, and R.M. Brenner Chronic progesterone antagonist-estradiol therapy suppresses breakthrough bleeding and endometrial proliferation in a menopausal macaque model Hum. Reprod., December 1, 2006; 21(12): 3081 - 3090. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Jabbour, R. W. Kelly, H. M. Fraser, and H. O. D. Critchley Endocrine Regulation of Menstruation Endocr. Rev., February 1, 2006; 27(1): 17 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I. M. Spitz Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications Hum. Reprod. Update, May 1, 2005; 11(3): 293 - 307. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |